The Journal of clinical endocrinology and metabolism · 2025
The Effects of the AGE Inhibitor Pyridoxamine on Bone in Older Women With Type 2 Diabetes: A Randomized Clinical Trial.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Brossfield Aiden V, McMahon Donald J, Fernando Jason, Omeragic Beatriz, Majeed Rukshana, Agarwal Sanchita, Sroga Grazyna E, Wang Bowen, Vashishth Deepak, Rubin Mishaela R
Аннотация
CONTEXT: Patients with type 2 diabetes (T2D) have reduced bone turnover and increased fractures. Advanced glycation end products (AGEs) impair osteoblasts and are implicated in diabetic fractures. Pyridoxamine (PM) is a vitamin B6 metabolite that inhibits formation of AGEs.
OBJECTIVE: We hypothesized that PM treatment in older patients with T2D, by inhibiting AGEs, would increase bone formation.
METHODS: This was a double-blind randomized controlled trial at an academic center. Older women with T2D were included (n = 55). Oral PM 200 mg twice daily for 1 year was given. The primary outcome was the change in the bone formation marker P1NP. Other outcomes were changes in bone resorption, bone mineral density (BMD), HbA1c, and skin autofluorescence (SAF), and in a bone biopsy subgroup, the correlation between bone fluorescent AGEs (fAGEs) and SAF.
RESULTS: P1NP increased 23.0% with PM (95% CI 9, 37; within group P = .028) vs 4.1% with placebo (-9, 17; within group P = .576; between groups P = .056). BMD increased at the femoral neck (PM 2.6 ± 5% vs placebo -0.9 ± 4%; between groups P = .007). Bone resorption markers and SAF did not change. HbA1c decreased (PM -0.38 ± 0.7% vs placebo 0.05 ± 1.7%; between groups P = .04). Within the PM group, the HbA1c change correlated inversely with the % P1NP change (r = -0.50, P = .034). Cortical bone biopsy fAGEs correlated with SAF (r = 0.86, P = .001). Adverse events were similar between groups.
CONCLUSION: PM tended to increase P1NP in older women with T2D, as well as increasing bone density and reducing HbA1c. Further studies are needed to investigate the potential of PM as a disease mechanism-directed approach to reduce fractures in T2D.
OBJECTIVE: We hypothesized that PM treatment in older patients with T2D, by inhibiting AGEs, would increase bone formation.
METHODS: This was a double-blind randomized controlled trial at an academic center. Older women with T2D were included (n = 55). Oral PM 200 mg twice daily for 1 year was given. The primary outcome was the change in the bone formation marker P1NP. Other outcomes were changes in bone resorption, bone mineral density (BMD), HbA1c, and skin autofluorescence (SAF), and in a bone biopsy subgroup, the correlation between bone fluorescent AGEs (fAGEs) and SAF.
RESULTS: P1NP increased 23.0% with PM (95% CI 9, 37; within group P = .028) vs 4.1% with placebo (-9, 17; within group P = .576; between groups P = .056). BMD increased at the femoral neck (PM 2.6 ± 5% vs placebo -0.9 ± 4%; between groups P = .007). Bone resorption markers and SAF did not change. HbA1c decreased (PM -0.38 ± 0.7% vs placebo 0.05 ± 1.7%; between groups P = .04). Within the PM group, the HbA1c change correlated inversely with the % P1NP change (r = -0.50, P = .034). Cortical bone biopsy fAGEs correlated with SAF (r = 0.86, P = .001). Adverse events were similar between groups.
CONCLUSION: PM tended to increase P1NP in older women with T2D, as well as increasing bone density and reducing HbA1c. Further studies are needed to investigate the potential of PM as a disease mechanism-directed approach to reduce fractures in T2D.